Bristol Myers Squibb (CGT Mfg) vs WuXi Biologics: CDMO Comparison
How does Bristol Myers Squibb (CGT Mfg) compare to WuXi Biologics?
As of Jul 2026, Bristol Myers Squibb (CGT Mfg): 8 FDA inspections (including 4 NAI, 4 VAI and 0 OAI), 2 EMA/MHRA GMP certificates. Signal Score 87. WuXi Biologics: 1 FDA inspection (including 0 NAI, 1 VAI and 0 OAI), 4 EMA/MHRA GMP certificates. Signal Score 82.7. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.
Side-by-side comparison of Bristol Myers Squibb (CGT Mfg) and WuXi Biologics on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Bristol Myers Squibb (CGT Mfg) has more FDA inspections on record (8 vs 1) — a deeper regulatory paper trail.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Bristol Myers Squibb (CGT Mfg) appears as a manufacturing partner on more matched clinical programs (586 vs 0) — a broader sponsor book.
Across the cross-modality scorecard, Bristol Myers Squibb (CGT Mfg) carries the higher composite Signal Score — but the right choice depends on the specific modality, phase, and geography of the program.
Frequently asked: Bristol Myers Squibb (CGT Mfg) vs WuXi Biologics
How does Bristol Myers Squibb (CGT Mfg) compare to WuXi Biologics?
On CDMO Signal's composite Signal Score, Bristol Myers Squibb (CGT Mfg) is 87/100 and WuXi Biologics is 83/100; Bristol Myers Squibb (CGT Mfg) has 8 FDA inspections on record vs 1 for WuXi Biologics; European coverage is 2 active EMA+MHRA certificates for Bristol Myers Squibb (CGT Mfg) vs 4 for WuXi Biologics. Both are tracked in the CDMO Signal directory. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Bristol Myers Squibb (CGT Mfg) or WuXi Biologics?
Both Bristol Myers Squibb (CGT Mfg) and WuXi Biologics maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Bristol Myers Squibb (CGT Mfg) has 8 FDA inspections on record; WuXi Biologics has 1.
How do Bristol Myers Squibb (CGT Mfg) and WuXi Biologics compare on European GMP coverage?
Bristol Myers Squibb (CGT Mfg) holds 1 active EMA GMP certificate and 1 MHRA / UK certificate. WuXi Biologics holds 3 active EMA GMP certificates and 1 MHRA / UK certificate. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is more active in clinical-stage manufacturing — Bristol Myers Squibb (CGT Mfg) or WuXi Biologics?
Bristol Myers Squibb (CGT Mfg) is matched to 586 ClinicalTrials.gov records as a manufacturing partner; WuXi Biologics is matched to 0. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
What does the Signal Score gap mean in practice?
Bristol Myers Squibb (CGT Mfg) carries a Signal Score of 87/100 and WuXi Biologics carries 83/100 — essentially tied for Bristol Myers Squibb (CGT Mfg). The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →